HLB Therapeutics Co Ltd
115450
Company Profile
Business description
HLB Therapeutics Co Ltd is a biotech company that pursues first-in-class and innovates new drug development. With the development and validation of new drugs for various hard-to-treat disorders, HLB Therapeutics is becoming a biopharmaceutical company focused on alleviating patient suffering.
Contact
22F, Parkview Tower
6, Jeongja-Dong, Bundang-Gu
Seongnam-si463-811
KORT: +82 317867800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
95
Stocks News & Analysis
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,023.30 | 56.60 | 0.63% |
| CAC 40 | 7,857.36 | 56.48 | 0.72% |
| DAX 40 | 24,217.37 | 247.01 | 1.03% |
| Dow JONES (US) | 44,632.99 | 204.57 | -0.46% |
| FTSE 100 | 9,136.32 | 54.88 | 0.60% |
| HKSE | 25,473.40 | 51.05 | -0.20% |
| NASDAQ | 21,098.29 | 80.29 | -0.38% |
| Nikkei 225 | 40,682.14 | 7.59 | 0.02% |
| NZX 50 Index | 12,961.28 | 24.87 | 0.19% |
| S&P 500 | 6,370.86 | 18.91 | -0.30% |
| S&P/ASX 200 | 8,764.10 | 59.50 | 0.68% |
| SSE Composite Index | 3,632.41 | 22.70 | 0.63% |